Skip NavigationSkip to Content
Return Return to Search Results

Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study

  1. Author:
    Terpos, Evangelos [ORCID]
    Politou, Marianna
    Sergentanis, Theodoros N
    Mentis, Andreas
    Rosati,Margherita
    Stellas,Dimitris [ORCID]
    Bear,Jenifer [ORCID]
    Hu,Xintao
    Felber,Barbara
    Pappa, Vassiliki
    Pagoni, Maria
    Grouzi, Elisavet
    Labropoulou, Stavroula
    Charitaki, Ioanna
    Ntanasis-Stathopoulos, Ioannis
    Moschandreou, Dimitra
    Bouhla, Anthi
    Saridakis, Stylianos
    Korompoki, Eleni
    Giatra, Chara
    Bagratuni, Tina
    Pefanis, Angelos
    Papageorgiou, Sotirios
    Spyridonidis, Alexandros
    Antoniadou, Anastasia
    Kotanidou, Anastasia
    Syrigos, Konstantinos
    Stamoulis, Konstantinos
    Panayiotakopoulos, George
    Tsiodras, Sotirios
    Alexopoulos, Leonidas
    Dimopoulos, Meletios A [ORCID]
    Pavlakis,George [ORCID]

  2. Author Address

    Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece., Hematology Laboratory Blood Bank, Aretaieion Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece., Public Health Laboratories, Hellenic Pasteur Institute, 11521 Athens, Greece., Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA., Institute of Chemical Biology, National Hellenic Research Foundation, 48 Vassileos Constantinou Ave., 11635 Athens, Greece., Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA., Hematology Unit, Second Department of Internal Medicine, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece., BMT Unit, Department of Hematology and Lymphomas, Evangelismos General Hospital, 10676 Athens, Greece., Department of Transfusion Service and Clinical Hemostasis, "Saint Savvas" Oncology Hospital, 11522 Athens, Greece., Blood Bank, Evangelismos General Hospital, 10442 Athens, Greece., Department of Internal Medicine, Sotiria General Hospital of Chest Diseases, 11527 Athens, Greece., BMT Unit, University Hospital of Patras, School of Medicine, University of Patras, 26500 Patras, Greece., Fourth Department of Internal Medicine, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece., First Department of Critical Care Medicine and Pulmonary Services, Evangelismos General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece., Oncology Unit, Third Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece., Hellenic National Blood Transfusion Center, 13678 Athens, Greece., Pharmacology Laboratory, School of Medicine, University of Patras, 26500 Patras, Greece., National Public Health Organization, 15123 Athens, Greece., Biomedical Systems Laboratory, National Technical University of Athens, 11527 Athens, Greece.,
    1. Year: 2020
    2. Date: Nov 28
    3. Epub Date: 2020 11 28
  2. Journal: Microorganisms
    1. 8
    2. 12
    3. Pages: pii: E1885
  4. Type of Article: Article
  5. Article Number: ARTN 1885
  6. ISSN: 2076-2607
  1. Abstract:

    We evaluated the antibody responses in 259 potential convalescent plasma donors for Covid-19 patients. Different assays were used: a commercial ELISA detecting antibodies against the recombinant spike protein (S1); a multiplex assay detecting total and specific antibody isotypes against three SARS-CoV-2 antigens (S1, basic nucleocapsid (N) protein and receptor-binding domain (RBD)); and an in-house ELISA detecting antibodies to complete spike, RBD and N in 60 of these donors. Neutralizing antibodies (NAb) were also evaluated in these 60 donors. Analyzed samples were collected at a median time of 62 (14-104) days from the day of first symptoms or positive PCR (for asymptomatic patients). Anti-SARS-CoV-2 antibodies were detected in 88% and 87.8% of donors using the ELISA and the multiplex assay, respectively. The multivariate analysis showed that age =50 years (p < 0.001) and need for hospitalization (p < 0.001) correlated with higher antibody titers, while asymptomatic status (p < 0.001) and testing >60 days after symptom onset (p = 0.001) correlated with lower titers. Interestingly, pseudotype virus-neutralizing antibodies (PsNAbs) significantly correlated with spike and with RBD antibodies by ELISA. Sera with high PsNAb also showed a strong ability to neutralize active SARS-CoV-2 virus, with hospitalized patients showing higher titers. Therefore, convalescent plasma donors can be selected based on the presence of high RBD antibody titers.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.3390/microorganisms8121885
  3. PMID: 33260775
  4. View record in Web of Science®
  5. WOS: 000603106900001
  6. PII : microorganisms8121885

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel